To further validate PRL-3-mediated dephosphorylation of Y783 of integrin β1, chemical inhibitor of PRL-3 (P0108), which has been shown to specifically inhibit PRL-3 phosphatase activity and decrease PRL-3-mediated cancer cell migration and invasion[15,25], was used to treat BGC823 and SW480 cells. This evidence concerns the gene PTP4A3 and cancer.